Powder: -20°C for 3 years | In solvent: -80°C for 2 years
Belizatinib is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 36.00 | |
2 mg | In stock | $ 52.00 | |
5 mg | In stock | $ 89.00 | |
10 mg | In stock | $ 143.00 | |
25 mg | In stock | $ 288.00 | |
50 mg | In stock | $ 397.00 | |
100 mg | In stock | $ 556.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 113.00 |
Description | Belizatinib is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC. |
Targets&IC50 | ALK:0.7 nM |
In vitro | In the Clinicalal trials, Belizatinib has antitumor activity. |
In vivo | In mouse models, Belizatinib can continuously and effectively inhibit ALK-dependent tumor growth. |
Synonyms | TSR-011 |
Molecular Weight | 577.75 |
Formula | C33H44FN5O3 |
CAS No. | 1357920-84-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 2 years
DMSO: 300 mg/mL
( < 1 mg/ml refers to the product slightly soluble or insoluble )
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Belizatinib 1357920-84-3 Angiogenesis Tyrosine Kinase/Adaptors ALK Trk receptor TSR011 Trk Receptor CD246 ALK tyrosine kinase receptor Tropomyosin related kinase receptor TSR 011 inhibit Cluster of differentiation 246 Inhibitor Anaplastic lymphoma kinase TSR-011 Anaplastic lymphoma kinase (ALK) inhibitor